Mr. Kamath brings more than 25 years of market access, pricing, and commercial operations experience to Tonix On August 15, 2025, the U.S. Food and Drug Administration approved Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, the first new fibromyalgia therapy in more than 15 years US Launch of Tonmya expected in the fourth quarter of 2025 CHATHAM, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Compan ...

美股期货市场表现 - 美国股指期货走低 道指期货下跌超过100点 [1] Energy Fuels Inc (UUUU) - 公司宣布拟进行5.5亿美元2031年到期的可转换优先票据私募发行 [1] - 股价在盘前交易中下跌6.4%至15.47美元 [1] Epsium Enterprise Limited (EPSM) - 股价在盘前交易中下跌24.3%至18.60美元 此前周一已下跌30% [3] JFB Construction Holdings (JFB) - 股价在盘前交易中下跌12.9%至11.06美元 [3] - 公司此前周一宣布4400万美元私募配售后股价飙升85% [3] bioAffinity Technologies Inc (BIAF) - 股价在盘前交易中下跌11.1%至2.89美元 [3] - 公司宣布完成480万美元公开发行定价 [3] Firefly Aerospace Inc (FLY) - 股价在盘前交易中下跌9.7%至33.36美元 [3] - 公司报告其下一次任务的Alpha火箭核心级在测试事故中被毁 [3] USBC, Inc. (USBC) - 股价在盘前交易中下跌6.7%至1.26美元 此前周一大涨16% [3] Tilray Brands, Inc. (TLRY) - 股价在盘前交易中下跌5.4%至1.75美元 [3] - 公司股价周一大涨超过60% 因前总统特朗普分享讨论CBD对老年人潜在益处的视频 [3] First Majestic Silver Corp. (AG) - 股价在盘前交易中下跌4.8%至11.80美元 [3] LuxExperience B.V. (LUXE) - 股价在盘前交易中下跌4.5%至8.07美元 [3]

OS Therapies Provides OST-HER2 UK MHRA and US FDA Osteosarcoma Regulatory UpdateSeptember 30, 2025 7:40 AM EDT | Source: OS TherapiesCompany updates sequence of OST-HER2 regulatory submissions, prioritizing UK MHRA conditional Marketing Authorisation Application (MAA) submission following positive August 2025 Scientific Advice Meeting feedback from UK MHRAIn principle, UK MHRA accepts use of historical control arm to support conditional MAAUK MHRA conditional MAA and US FDA Biologics Licensing ...

The DAT era is here. | Credit: Credit: Raymond Boyd/Getty Images.. Key Takeaways Digital Asset Treasuries are publicly traded firms dedicated to accumulating crypto. Aethir is a DePIN project offering GPU-as-a-service solutions for AI, gaming, and cloud. Binance Coin treasuries currently comprise over $500 million worth of BNB. Two new Digital Asset Treasuries (DATs) from two separate biotech firms are set to launch after raising a combined $402 million in private placements to acquire huge sums o ...

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it has enrolled the first patient in TRUST-IV (NCT07154706), a Phase 3 study evaluating the efficacy and safety of IBTROZIâ"¢ (taletrectinib), a next-generation ROS1 inhibitor, versus placebo for the adjuvant treatment of patients with resected ROS1-positive (ROS1+) early-stage non-small cell lung cancer (NSCLC). "While surgi. ...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced a late-breaking poster presentation at the 30th Annual International Congress of the World Muscle Society (WMS) being held October 7-12, 2025, in Vienna, Austria. "We look forward to sharing the latest preclinical data for PBGENE-DMD at the upcoming. ...

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in BMRN over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking ...

Accessibility StatementSkip Navigation CollPlant is now moving towards clinical trials and scaling and optimizing its manufacturing to ensure readiness for the upcoming clinical trials REHOVOT, Israel, Sept. 30, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing disruptive technologies and products based on its proprietary non-animal recombinant human collagen (rhCollagen), today announced positive results from its non-clinical program eva ...

Ronen Twito, Kadimastem's Executive Chairman and CEO and Alexander C. Zwyer NLS's CEO & Executive Board Member stated: ""We are grateful to our shareholders for their strong support of the merger. Today's outcome marks a pivotal step in creating NewCelX, a transatlantic biopharma leader†The merger will create: Nasdaq-listed company: Under the symbol "NCEL": Governance and capital structure approvals completed Diversified pipeline: Unites Kadimastem's advanced cell therapy programs (including a Phase 2a AL ...

Clinical benefit for efzofitimod across multiple disease-related health outcomes reported. Improvement in Fatigue Assessment Scale Total Score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0226). Improvement in King’s Sarcoidosis Questionnaire-General Health score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0197). SAN DIEGO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage b ...